Metastatic cutaneous squamous cell carcinoma
Also known as: Metastatic squamous cell carcinoma / Squamous cell carcinoma, metastatic (morphologic abnormality) / Metastatic squamous cell carcinoma (disorder) / [M]Squamous cell carcinoma, metastatic NOS (morphologic abnormality)
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB14707 | Cemiplimab | A programmed death receptor-1 blocking antibody used to treat cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer. |
| DB09037 | Pembrolizumab | A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma. |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB14707 | Cemiplimab | Programmed cell death protein 1 | target |
| DB09037 | Pembrolizumab | Programmed cell death protein 1 | target |
| DB09037 | Pembrolizumab | Programmed cell death 1 ligand 1 | target |
| Drug | Drug Name | Phase | Status | Count |
|---|---|---|---|---|
| DB14707 | Cemiplimab | 1 / 2 | Active Not Recruiting | 1 |
| DB09037 | Pembrolizumab | 1 / 2 | Active Not Recruiting | 1 |
| DB14707 | Cemiplimab | 2 | Active Not Recruiting | 1 |